Key result
Urotensin II administration produced vasoconstriction of the cutaneous microcirculation in cirrhotic patients and vasodilatation in healthy controls (p=0.01 at 10^-9 mol; p=0.004 at 10^-7 mol).
Why the study?
Does Urotensin II administration alter vascular tone in patients with liver cirrhosis compared to healthy controls?
Does Urotensin II administration alter vascular tone in patients with liver cirrhosis compared to healthy controls?
p-value: p=0.01 and 0.004
Urotensin II mediates vasoconstriction in the microcirculation of cirrhotic patients but causes vasodilatation in healthy controls, suggesting a pathophysiological role in portal hypertension.
Differential urotensin II response in cirrhosis warrants caution; hypothesis-generating for portal hypertension role, needs prospective validation.
OBJECTIVE: Urotensin II (UII) is now recognized as the most potent human vasoconstrictor. Although its role in human pathophysiology is unknown, vasoactive mediators are known to be important in the pathogenesis of portal hypertension complicating chronic liver disease. The objective of this study was to investigate the role of UII in liver cirrhosis via examination of the in vivo effect of UII in this patient group. MATERIAL AND METHODS: The vasoactive effects of UII were measured using Laser Doppler velocimetry on cirrhotic patients (n = 14) and age-matched healthy controls (n = 14) after UII administration by iontophoresis to the cutaneous microcirculation of the forearm. RESULTS: In vivo administration of UII produced vasoconstriction of the cutaneous microcirculation in the cirrhotic group and vasodilatation in the controls, with values differing significantly at the two highest doses of UII: 10(-9) mol (p = 0.01) and 10(-7) mol (p = 0.004). CONCLUSIONS: UII mediates vasoconstriction of the microcirculation of cirrhotics but not of controls. This suggests that UII has pathophysiological relevance in the portal hypertensive population through its vasoactive properties. Further studies of UII and UII-antagonists are warranted in this patient population.
No takes yet. Share an insight, caveat, or question.
Kemp et al. (2007) studied Liver cirrhosis (n=28). Urotensin II (UII) vs. Healthy controls was evaluated on Vasoactive effects on the cutaneous microcirculation (p=0.01 and 0.004). Urotensin II administration produced vasoconstriction of the cutaneous microcirculation in cirrhotic patients and vasodilatation in healthy controls (p=0.01 at 10^-9 mol; p=0.004 at 10^-7 mol).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: